Abstract
Abstract Introduction: High body mass index (BMI) is considered a risk factor for breast cancer onset and is correlated with bad prognosis in breast cancer patients. However, very few studies have associated clinical and molecular tumor characteristics with the patients’ BMI at the time of breast cancer diagnosis. The present study analyses how BMI influences tumor biology and correlates with different molecular subtypes according to menopausal status in a large cohort of patients with new diagnoses of early breast cancer (EBC). Methods: Overall 967 patients with a new diagnosis of EBC from 2007 till 2012 were recruited for this study. Clinical and tumor characteristics such as age, menopausal status, weight, height, tumor size (T), grading, estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2) status, were prospectively collected. BMI was categorized into two groups (low: ≤25; high: >25). Associations between BMI and clinicopathological variables were performed by χ2 test. Results: A total of 594 (61%) post-menopause and 373 (39%) pre-menopause women were enrolled. Regardless of menopausal status, patients with high BMI were older (p<0.0001) and had larger tumors (p<0.0001). However, among postmenopausal patients, high BMI correlates with increased ER expression (p = 0.015), lower HER2 expression (p = 0.05) and less aggressive tumor subtypes as luminal A (p = 0.043). In the same patient subset, women with low BMI were more likely to develop a Luminal B, HER2 like or TN breast cancer. No correlation was observed between tumor molecular phenotypes and BMI among premenopausal women. Conclusion: Among postmenopausal patient, high BMI is associated with less aggressive and more endocrine sensitive EBC. This is consistent with the hypotheses that higher estrogen exposure of breast tissue in women with higher BMI may drive growth of these cancers. If further confirmed, our data suggests that weight control in this subset of women may help to prevent cancer development. Table 1Clinical and Molecular CharacteristicsBMI ≤25BMI>25 N%N%totalp valueER .015Positive15376.132884.3481 Negative4823.96115.7109 PgR .2Positive14471.629676.1440 Negative5728.49323.9150 HER2 .05Positive3819.55013.388 Negative15780.532786.7484 MOLECULAR SUBTYPES .043Luminal A11560.225771.2372 Luminal B3015.74813.378 HER2147.3143.928 TN3216.84211.674 Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-06-15.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
